Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) have been assigned a consensus recommendation of “Buy” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $51.90.
DCPH has been the subject of several recent analyst reports. Cantor Fitzgerald lifted their target price on shares of Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a report on Friday, October 4th. Piper Jaffray Companies set a $55.00 target price on shares of Deciphera Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 30th. SunTrust Banks lifted their target price on shares of Deciphera Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $65.00 target price (up from $50.00) on shares of Deciphera Pharmaceuticals in a report on Wednesday, August 14th.
In other news, insider Daniel Lee Flynn sold 148,107 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $40.92, for a total transaction of $6,060,538.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Douglas Taylor sold 22,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $34.97, for a total transaction of $786,825.00. Insiders sold 576,107 shares of company stock valued at $21,748,018 over the last ninety days. Corporate insiders own 7.02% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC raised its holdings in shares of Deciphera Pharmaceuticals by 55.7% during the second quarter. Cubist Systematic Strategies LLC now owns 13,563 shares of the company’s stock valued at $306,000 after purchasing an additional 4,854 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Deciphera Pharmaceuticals during the second quarter valued at approximately $4,606,000. Morgan Stanley raised its holdings in shares of Deciphera Pharmaceuticals by 214.8% during the second quarter. Morgan Stanley now owns 7,864 shares of the company’s stock valued at $177,000 after purchasing an additional 5,366 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Deciphera Pharmaceuticals by 4.2% during the second quarter. Bank of America Corp DE now owns 26,052 shares of the company’s stock valued at $588,000 after purchasing an additional 1,062 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Deciphera Pharmaceuticals by 2.6% during the second quarter. Vanguard Group Inc. now owns 792,654 shares of the company’s stock valued at $17,874,000 after purchasing an additional 20,252 shares during the last quarter. 45.68% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ DCPH opened at $32.54 on Monday. Deciphera Pharmaceuticals has a 1 year low of $18.55 and a 1 year high of $42.99. The stock has a market cap of $1.61 billion, a P/E ratio of -11.54 and a beta of 1.89. The firm has a 50-day moving average of $35.54 and a 200 day moving average of $26.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.26 and a quick ratio of 7.26.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.56. The business had revenue of $25.00 million for the quarter, compared to analysts’ expectations of $20.00 million. Research analysts expect that Deciphera Pharmaceuticals will post -4.05 earnings per share for the current fiscal year.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Story: Does the discount rate affect the economy?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.